Flunisolide, the active component of AEROSPAN (flunisolide) Inhalation Aerosol, is a corticosteroid.
AEROSPAN Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. AEROSPAN Inhalation Aerosol is also indicated for asthma patients requiring oral corticosteroid therapy, where adding AEROSPAN Inhalation Aerosol may reduce or eliminate the need for oral corticosteroids.
Important Limitations of Use
AEROSPAN Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.
AEROSPAN Inhalation Aerosol is NOT indicated in children less than 6 years of age.
Media Articles Related to Aerospan (Flunisolide Inhalation)
How a throw-away paper cup can save the life of a child with asthma
Source: Respiratory / Asthma News From Medical News Today [2015.08.21]
A disposable cup - favoured by many of the high street's well known coffee shops - is the inspiration behind a new and scientifically reviewed device for the safe and prompt treatment of school age...
Study reveals new insights into how asthma 'pathways' could be blocked
Source: Respiratory / Asthma News From Medical News Today [2015.08.20]
University of Leicester researchers involved in study demonstrating how combining novel treatments currently in development may lead to better asthma controlResearchers from the University of...
Asthma Myths Pictures Slideshow
Source: MedicineNet Asthma Complexities Specialty [2015.08.19]
Title: Asthma Myths Pictures Slideshow
Created: 12/15/2008 12:00:00 AM
Last Editorial Review: 8/19/2015 12:00:00 AM
Exploring 'clinical conundrum' of asthma-COPD overlap in nonsmokers with chronic asthma
Source: Respiratory / Asthma News From Medical News Today [2015.08.06]
Researchers may be closer to finding the mechanism responsible for loss of lung elastic recoil and airflow limitation in nonsmokers with chronic asthma.
Add Asthma, Allergy Plans to Your Back-to-School List
Source: MedicineNet Allergy Specialty [2015.08.03]
Title: Add Asthma, Allergy Plans to Your Back-to-School List
Category: Health News
Created: 8/1/2015 12:00:00 AM
Last Editorial Review: 8/3/2015 12:00:00 AM
Published Studies Related to Aerospan (Flunisolide Inhalation)
Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. [2011.10]
BACKGROUND: Inhaled corticosteroids (ICS) are the preferred long-term therapy for subjects with persistent asthma. However, concerns remain about potential effects of long-term ICS use on growth in children. OBJECTIVE: To determine the effect of 1 year of inhalation therapy with flunisolide hydrofluoroalkane (HFA) on growth velocity and bone maturation in children with mild persistent asthma... CONCLUSIONS: In this study, flunisolide HFA did not suppress growth or bone maturation at the highest approved dose for children with persistent asthma. Copyright (c) 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Intranasal flunisolide treatment in patients with non-allergic rhinitis. [2011.04]
Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation...
High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. [2009.04]
The role of inhaled corticosteroids in asthma exacerbation is debated. We compared high doses of nebulized budesonide versus high doses of nebulized flunisolide, in association with a short-acting beta-2-agonist, in the treatment of moderate asthma exacerbation in preschool children... High doses of inhaled flunisolide and budesonide are both effective in the management of moderate asthma exacerbations in pre-school-age children, but the flunisolide therapeutic effect was faster than budesonide.
Strength and endurance of the respiratory and handgrip muscles after the use of flunisolide in normal subjects. [2007.07]
OBJECTIVE: To evaluate the effects of the inhaled flunisolide upon the strength and endurance of the respiratory and peripheral muscles of normal subjects... CONCLUSION: Inhalation of flunisolide by normal subjects for 1 month does not cause any acute or clinically perceived effect in the peripheral or respiratory muscles.
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. [2006.01]
Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases...
Clinical Trials Related to Aerospan (Flunisolide Inhalation)
Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) [Completed]
The objective of this cross-over study is to validate the Preference Module of the EARNS-Q in
adult subjects (>=18 years of age) with Seasonal Allergic Rhinitis (SAR) taking
beclomethasone dipropionate and beclomethasone dipropionate and flunisolide.
Mentored Patient-Oriented Research Career Development Award [Recruiting]
Asthmatics have inflammation in the large airways (tubes through which air travels in and
out of the lungs). The large airways are located in the central lung. New research shows
that asthmatics also have inflammation in the small airways. The small airways are located
in the peripheral lung (the parts of the lung away from the central lung).
Until now, most of the inhaled medications available have been made up of big particles that
never reach the peripheral lung. The purpose of this study is to try to measure the level of
inflammation in the peripheral lung in asthmatics and see if this inflammation can be
decreased with different types of inhaled corticosteroids. The investigators will check
airway inflammation before and after use of an inhaled corticosteroid that has a large
particle size and should only reach the large airways (Flunisolide-CFC), and before and
after use of an inhaled, small particle corticosteroid that should reach both the large and
small airways (Flunisolide-HFA).
Subjects will make 6 study visits over two phases of the study. In the first phase, the
investigators will collect baseline information about subjects while they are using placebo
(inactive substance). In the second phase, subjects will take either the large or small
Visits will involve questionnaires and various tests measuring lung function (such as
spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be
measured as an indication of inflammation. Subjects will also measure and make note of lung
function at home twice daily using a peak expiratory flow meter. Two of the visits will
involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue
samples without surgery. Another two of the visits will involve the use of high resolution
computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the